Answers are grounded in this paper and cite their sources.
A case report reveals long-term disease-free survival after metastasectomy in a bladder cancer survivor, suggesting effective management pathways.
Urothelial carcinoma of the bladder most commonly metastasizes to lymph nodes, liver, bone, and lung. Solitary pulmonary metastasis from superficial (non-muscle-invasive) bladder cancer (NMIBC) is exceptionally rare. Furthermore, the long-term sequelae and subsequent cancer risk in such patients remain poorly defined. We report a case of a 76-year-old male with a history of high-grade T1 NMIBC who was found to have a solitary pulmonary nodule 19 months after completing Bacillus Calmette-Guérin (BCG) intravesical therapy. The patient underwent a successful pulmonary metastasectomy, with histopathology confirming metastatic urothelial carcinoma. He remained disease-free for seven years. Surprisingly, he then presented with de novo muscle-invasive bladder cancer (MIBC) without evidence of distant recurrence. He was managed conservatively being of old age and poor performance. This case highlights two rare phenomena: (1) the potential for superficial bladder cancer to distant metastases, and (2) the development of a new, aggressive primary tumor in the bladder long time after the control of metastatic disease. It underscores the importance of long-term, multidisciplinary surveillance for bladder cancer survivors, the biological heterogeneity of urothelial carcinoma, and the curative potential of metastasectomy in selected patients.
No takes yet. Share an insight, caveat, or question.
Alhilaly et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: